Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome-Reference-Cited by-同舟云学术

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

Published:2023-07 Issue:7 Volume:29 Page:438.e1-438.e16
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Hines Melissa R.,Knight Tristan E.^ORCID,McNerney Kevin O.^ORCID,Leick Mark B.^ORCID,Jain Tania^ORCID,Ahmed Sairah,Frigault Matthew J.^ORCID,Hill Joshua A.^ORCID,Jain Michael D.^ORCID,Johnson William T.,Lin Yi^ORCID,Mahadeo Kris M.,Maron Gabriela M.^ORCID,Marsh Rebecca A.,Neelapu Sattva S.,Nikiforow Sarah,Ombrello Amanda K.,Shah Nirav N.^ORCID,Talleur Aimee C.^ORCID,Turicek David^ORCID,Vatsayan Anant^ORCID,Wong Sandy W.,Maus Marcela V.^ORCID,Komanduri Krishna V.,Berliner Nancy,Henter Jan-Inge^ORCID,Perales Miguel-Angel^ORCID,Frey Noelle V.^ORCID,Teachey David T.^ORCID,Frank Matthew J.,Shah Nirali N.^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference153 articles.

1. Pediatric hemophagocytic lymphohistiocytosis;Canna;Blood,2020

2. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults;La Rosee;Blood,2019

3. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

4. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia;Fitzgerald;Crit Care Med,2017

5. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia;Teachey;Cancer Discov,2016

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies;Blood;2024-09-12

2. Myeloma CAR T-cell therapy toxicity timing: What is the right amount of post-treatment monitoring for our patients?;Transplantation and Cellular Therapy;2024-09

3. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey;Frontiers in Medicine;2024-08-28

4. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26

5. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities;Intensive Care Medicine;2024-08-22